## Claims

- 1. An agent for elevating dendritic cell precursor level in the blood which comprises an agonist to a receptor expressed in immature dendritic cells or a functional derivative thereof as the active ingredient.
- 2. An agent for elevating dendritic cell precursor level in the blood which comprises an agonist to receptor CCR1 or CCR5 or a functional derivative thereof as the active ingredient.
- 3. An agent for elevating dendritic cell precursor level in the blood as claimed in claim 2 wherein the agonist is selected form among MIP-1 $\alpha$ , MIP-1 $\beta$ , RANTES, MARC, LCC-1(ref), MCP-3 and MCP-4.
- 4. An agent for elevating dendritic cell precursor level in the blood as claimed in claim 2 wherein the agonist is selected from among MIP-1 $\alpha$ , RANTES, MARC and LCC-1(ref).
- 5. An agent for elevating dendritic cell precursor level in the blood as claimed in claim 2 wherein the agonist or a functional derivative thereof is MIP-1 $\alpha$  or a functional derivative thereof.
- 6. An agent for elevating dendritic cell precursor level in the blood as claimed in claim 5 wherein the functional derivative of MIP-1 $\alpha$  is BB-10010.
- 7. An agent for elevating dendritic cell precursor level in the blood as claimed in claim 1 wherein the functional

derivative of the agonist is an agonist to a receptor expressed in immature dendritic cells which is chemically modified with an amphipathic polymer.

- 8. An agent for elevating dendritic cell precursor level in the blood as claimed in claim 2 wherein the functional derivative of the agonist is an agonist to receptor CCR1 or CCR5 which is chemically modified with an amphipathic polymer.
- 9. An agent for elevating dendritic cell precursor level in the blood as claimed in claim 2 wherein the functional derivative of the agonist is MIP-1 $\alpha$ , MIP-1 $\beta$ , RANTES, MARC, LCC-1(ref), MCP-3 or MCP-4 which is chemically modified with an amphipathic polymer.
- 10. An agent for elevating dendritic cell precursor level in the blood as claimed in claim 2 wherein the functional derivative of the agonist is MIP-1 $\alpha$ , BB-10010, RANTES, MARC or LCC-1(ref) which is chemically modified with an amphipathic polymer.
- 11. An agent for elevating dendritic cell precursor level in the blood as claimed in claim 2 wherein the functional derivative of the agonist is MIP-1 $\alpha$  or BB-10010 which is chemically modified with an amphipathic polymer.
- 12. An agent for elevating dendritic cell precursor level in the blood as claimed in claim 2 wherein the functional derivative of the agonist is BB-10010 which is chemically modified with an amphipathic polymer.

- 13. An agent for elevating dendritic cell precursor level in the blood as claimed in any of claims 7 to 12 wherein the amphipathic polymer is a partially alkyl-esterified styrene-maleic acid copolymer.
- 14. An agonist to a receptor expressed in immature dendritic cells which is chemically modified with an amphipathic polymer.
- 15. An agonist to receptor CCR1 or CCR which is chemically modified with an amphipathic polymer.
- 16. An agonist as claimed in claim 15 which is MIP-1 $\alpha$ , BB-10010, MIP-1 $\beta$ , RANTES, MARC, LCC-1(ref), MCP-3 or MCP-4 which is chemically modified with an amphipathic polymer.
- 17. An agonist as claimed in claim 15 which is MIP-1 $\alpha$  chemically modified with an amphipathic polymer.
- 18. An agonist as claimed in claim 15 which is BB-10010 chemically modified with an amphipathic polymer.
- 19. An agonist as claimed in any of claims 14 to 18 wherein the amphipathic polymer is a partially alkyl-esterified styrene-maleic acid copolymer or a polyethylene glycol derivative.